Intensifying competition and concentration of sales among wholesalers
First written in FY2016. 32 of 34 entries say "Restated". Latest entry: FY2026.
3 other companies' latest entry also says "Restated".
- FY2026RestatedAnnual report
「Competition with products of other companies, including generic drugs, could reduce sales and earnings and have a material impact on operating results and financial condition. In addition, the Group's customers are concentrated among certain wholesalers, and if these wholesalers incur bad debts and the related receivables become uncollectible, this could have a material impact on operating results and financial condition.」
The risks arising from intensifying competition and concentration of customers among wholesalers, as well as measures involving preservation of product value and credit management, have been reconfirmed. - FY2026-H1RestatedAnnual report
「The pharmaceutical industry continues to face a challenging environment, with drug price revisions implemented every year while policies to restrain medical costs continue to be promoted.」
The recognition that the challenging business environment is continuing due to policies to restrain medical costs and annual drug price revisions has been reconfirmed. - FY2025RestatedAnnual report
「Competition with products of other companies, including generic drugs, could reduce sales and earnings and have a material impact on operating results and financial condition. In addition, the Group's customers are concentrated among certain wholesalers, and if these wholesalers incur bad debts and the related receivables become uncollectible, this could have a material impact on operating results and financial condition.」
The risks arising from intensifying competition and concentration of customers among wholesalers, as well as mitigation measures involving preservation of product value and credit management, have been reconfirmed. - FY2025-H1RestatedAnnual report
「The pharmaceutical industry continues to face a challenging environment, with drug price revisions implemented every year as policies to restrain medical costs continue to be promoted.」
The recognition that the challenging business environment is continuing due to policies to restrain medical costs and annual drug price revisions has been reconfirmed. - FY2024-Q3RestatedAnnual report
「While policies to restrain drug costs, driven by the issue of securing funding for social security expenditure, continue to be promoted in the pharmaceutical industry, an interim drug price revision was also implemented in April 2023. Competition among companies is also accelerating, and the industry continues to face a challenging business environment.」
The challenging business environment arising from policies to restrain drug costs, the April 2023 interim drug price revision and accelerating competition among companies has been reconfirmed. The disclosure states that there have been no material changes in business and other risks. - FY2024-Q2RestatedAnnual report
「While policies to restrain drug costs, driven by the issue of securing funding for social security expenditure, continue to be promoted in the pharmaceutical industry, an interim drug price revision was also implemented in April 2023. Competition among companies is also accelerating, and the industry continues to face a challenging business environment.」
The challenging business environment arising from policies to restrain drug costs, the April 2023 interim drug price revision and accelerating competition among companies has been reconfirmed. - FY2024-Q1RestatedAnnual report
「While policies to restrain drug costs, driven by the issue of securing funding for social security expenditure, continue to be promoted in the pharmaceutical industry, an interim drug price revision was also implemented in April 2023. Competition among companies is also accelerating, and the industry continues to face a challenging business environment.」
The challenging business environment arising from policies to restrain drug costs, the April 2023 interim drug price revision and accelerating competition among companies has been reconfirmed. - FY2023-Q3RestatedAnnual report
「The pharmaceutical industry continues to face a challenging business environment, as policies to restrain drug costs, driven by the issue of securing funding for social security expenditure, continue to be promoted and competition among companies is accelerating.」
The challenging business environment arising from ongoing policies to restrain drug costs and accelerating competition among companies has been reconfirmed. - FY2023-Q2RestatedAnnual report
「The pharmaceutical industry continues to face a challenging business environment, as policies to restrain drug costs, driven by the issue of securing funding for social security expenditure, continue to be promoted and competition among companies is accelerating.」
The challenging business environment arising from ongoing policies to restrain drug costs and accelerating competition among companies has been reconfirmed. - FY2023-Q1RestatedAnnual report
「The pharmaceutical industry continues to face a challenging business environment, as policies to restrain drug costs, driven by the issue of securing funding for social security expenditure, continue to be promoted and competition among companies is accelerating.」
The challenging business environment arising from ongoing policies to restrain drug costs and accelerating competition among companies has been reconfirmed. The disclosure states that there have been no material changes in business and other risks. - FY2022RestatedAnnual report
「Competition with products of other companies, including generic drugs, could reduce sales and earnings and have a material impact on operating results and financial condition. In addition, the Group's customers are concentrated among certain wholesalers.」
The risks arising from intensifying competition and concentration of customers among wholesalers have been reconfirmed. - FY2022-Q3RestatedAnnual report
「While policies to restrain drug costs, driven by the issue of securing funding for social security expenditure, continue to be promoted in the pharmaceutical industry, an interim drug price revision was implemented in April 2021. Competition among companies is also accelerating, and the industry continues to face a challenging business environment.」
The challenging business environment has been reconfirmed as continuing due to ongoing policies to restrain drug costs, the interim drug price revision and accelerating competition among companies. - FY2022-Q2RestatedAnnual report
「While policies to restrain drug costs, driven by the issue of securing funding for social security expenditure, continue to be promoted in the pharmaceutical industry, an interim drug price revision was implemented in April 2021. Competition among companies is also accelerating, and the industry continues to face a challenging business environment.」
The challenging business environment has been reconfirmed as continuing due to ongoing policies to restrain drug costs, the interim drug price revision and accelerating competition among companies. - FY2022-Q1RestatedAnnual report
「While policies to restrain drug costs, driven by the issue of securing funding for social security expenditure, continue to be promoted in the pharmaceutical industry, an interim drug price revision was implemented in April 2021. Competition among companies is also accelerating, and the industry continues to face a challenging business environment.」
The challenging business environment has been reconfirmed as continuing due to ongoing policies to restrain drug costs, the interim drug price revision and accelerating competition among companies. - FY2021RestatedAnnual report
「Competition with products of other companies, including generic drugs, could reduce sales and earnings and have a material impact on operating results and financial condition. In addition, the Group's customers are concentrated among certain wholesalers.」
The risks arising from intensifying competition and concentration of customers among wholesalers have been reconfirmed. - FY2021-Q3RestatedAnnual report
「The pharmaceutical industry continues to face a challenging business environment, as policies to restrain drug costs, driven by the issue of securing funding for social security expenditure, continue to be promoted and competition among companies is accelerating.」
The challenging business environment has been reconfirmed as continuing due to ongoing policies to restrain drug costs and accelerating competition among companies. - FY2021-Q2RestatedAnnual report
「The pharmaceutical industry continues to face a challenging business environment, as policies to restrain drug costs, driven by the issue of securing funding for social security expenditure, continue to be promoted and competition among companies is accelerating.」
The challenging business environment has been reconfirmed as continuing due to ongoing policies to restrain drug costs and accelerating competition among companies. - FY2021-Q1RestatedAnnual report
「The pharmaceutical industry continues to face a challenging business environment, as policies to restrain drug costs, driven by the issue of securing funding for social security expenditure, continue to be promoted and competition among companies is accelerating.」
The challenging business environment has been reconfirmed as continuing due to ongoing policies to restrain drug costs and accelerating competition among companies. - FY2020RestatedAnnual report
「Competition with products of other companies, including generic drugs, could reduce sales and earnings and have a material impact on operating results and financial condition. In addition, the Group's customers are concentrated among certain wholesalers.」
The risks arising from intensifying competition and concentration of customers among wholesalers are reiterated. - FY2020-Q3RestatedAnnual report
「The pharmaceutical industry continues to face a challenging business environment, as policies to restrain drug costs, driven by the issue of securing funding for social security expenditure, continue to be promoted and competition among companies is accelerating.」
The challenging business environment has been reconfirmed as continuing due to ongoing policies to restrain drug costs and accelerating competition among companies. - FY2020-Q2RestatedAnnual report
「The pharmaceutical industry continues to face a challenging business environment, as policies to restrain drug costs, driven by the issue of securing funding for social security expenditure, continue to be promoted and competition among companies is accelerating.」
The challenging business environment has been reconfirmed as continuing due to ongoing policies to restrain drug costs and accelerating competition among companies. The disclosure states that there have been no material changes in business and other risks. - FY2020-Q1RestatedAnnual report
「The pharmaceutical industry continues to face a challenging business environment, as policies to restrain drug costs, driven by the issue of securing funding for social security expenditure, continue to be promoted and competition among companies is accelerating.」
The challenging business environment has been reconfirmed as continuing due to ongoing policies to restrain drug costs and accelerating competition among companies. - FY2019RestatedAnnual report
「Competition with products of other companies, including generic drugs, could reduce sales and have a material impact on operating results and financial condition. In addition, the Group's customers are concentrated among certain wholesalers, and if these wholesalers incur bad debts, this could have a material impact on operating results and financial condition.」
The risks arising from intensifying competition and concentration of sales among wholesalers are reiterated. - FY2019-Q3RestatedAnnual report
「The pharmaceutical industry continues to face a challenging business environment, as policies to restrain drug costs, driven by the issue of securing funding for social security expenditure, continue to be promoted and competition among companies is accelerating.」
The challenging business environment has been reconfirmed as continuing due to ongoing policies to restrain drug costs and accelerating competition among companies. - FY2019-Q2RestatedAnnual report
「The pharmaceutical industry continues to face a challenging business environment, as policies to restrain drug costs, driven by the issue of securing funding for social security expenditure, continue to be promoted and competition among companies is accelerating.」
The challenging business environment has been reconfirmed as continuing due to ongoing policies to restrain drug costs and accelerating competition among companies. - FY2019-Q1RestatedAnnual report
「The pharmaceutical industry continues to face a challenging business environment, as policies to restrain drug costs, driven by the issue of securing funding for social security expenditure, continue to be promoted and competition among companies is accelerating.」
The challenging business environment has been reconfirmed as continuing due to ongoing policies to restrain drug costs and accelerating competition among companies. - FY2018RestatedAnnual report
「Competition with products of other companies, including generic drugs, could reduce sales and have a material impact on operating results and financial condition. In addition, the Group's customers are concentrated among certain wholesalers, and if these wholesalers incur bad debts, this could have a material impact on operating results and financial condition.」
The risks arising from intensifying competition and concentration of sales among wholesalers are reiterated. - FY2018-Q3RestatedAnnual report
「The pharmaceutical industry continues to face a challenging business environment, as policies to restrain drug costs, driven by the issue of securing funding for social security expenditure, continue to be promoted and competition among companies is accelerating.」
The challenging business environment has been reconfirmed as continuing due to ongoing policies to restrain drug costs and accelerating competition among companies. - FY2018-Q2RestatedAnnual report
「The pharmaceutical industry continues to face a challenging business environment, as policies to restrain drug costs, driven by the issue of securing funding for social security expenditure, continue to be promoted and competition among companies is accelerating.」
The challenging business environment has been reconfirmed as continuing due to ongoing policies to restrain drug costs and accelerating competition among companies. - FY2018-Q1RestatedAnnual report
「The pharmaceutical industry continues to face a challenging business environment, as policies to restrain drug costs, driven by the issue of securing funding for social security expenditure, continue to be promoted and competition among companies is accelerating.」
The challenging business environment has been reconfirmed as continuing due to ongoing policies to restrain drug costs and accelerating competition among companies. - FY2017-Q3RestatedAnnual report
「The pharmaceutical industry continues to face a challenging business environment, as policies to restrain drug costs, driven by the issue of securing funding for social security expenditure, continue to be promoted and competition among companies is accelerating.」
The challenging business environment has been reconfirmed as continuing due to ongoing policies to restrain drug costs and accelerating competition among companies. - FY2017-Q2RestatedAnnual report
「The pharmaceutical industry continues to face a challenging business environment, as policies to restrain drug costs, driven by the issue of securing funding for social security expenditure, continue to be promoted and competition among companies is accelerating.」
The challenging business environment has been reconfirmed as continuing due to ongoing policies to restrain drug costs and accelerating competition among companies. - FY2017-Q1WorsenedAnnual report
「The pharmaceutical industry continues to face a challenging business environment, as policies to restrain drug costs, driven by the issue of securing funding for social security expenditure, continue to be promoted and competition among companies is accelerating.」
The disclosure states that competition among companies is "accelerating," presenting the challenging competitive environment in stronger terms than in the previous year's disclosure. - FY2016First statedAnnual report
「Competition with products of other companies, including generic drugs, could reduce sales and have a material impact on operating results and financial condition. In addition, the Group's customers are concentrated among certain wholesalers, and if these wholesalers incur bad debts, this could have a material impact on operating results and financial condition.」
Competition risk and customer and sales-channel concentration risk are explained together.